Goldman Sachs Group Inc. trimmed its holdings in Teleflex Incorporated (NYSE:TFX) by 23.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 283,939 shares of the medical technology company’s stock after selling 85,597 shares during the period. Goldman Sachs Group Inc. owned 0.63% of Teleflex worth $70,649,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Aristotle Atlantic Partners LLC acquired a new stake in Teleflex in the 4th quarter worth about $202,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Teleflex in the 4th quarter valued at about $228,000. Checchi Capital Advisers LLC acquired a new position in shares of Teleflex in the 4th quarter valued at about $230,000. Coldstream Capital Management Inc. acquired a new position in shares of Teleflex in the 3rd quarter valued at about $226,000. Finally, Lourd Capital LLC acquired a new position in shares of Teleflex in the 4th quarter valued at about $266,000. 90.75% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on TFX. TheStreet lowered Teleflex from an “a-” rating to a “c+” rating in a research note on Monday, March 12th. ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Leerink Swann reaffirmed a “buy” rating and issued a $321.00 price objective (up from $307.00) on shares of Teleflex in a research note on Tuesday, January 30th. Finally, Stephens reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Teleflex in a research note on Thursday, January 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $281.56.
Teleflex Incorporated (TFX) opened at $264.76 on Friday. The firm has a market capitalization of $11,979.95, a PE ratio of 31.66, a PEG ratio of 1.96 and a beta of 1.22. Teleflex Incorporated has a 52 week low of $191.04 and a 52 week high of $288.78. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 0.89.
Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 22nd. The medical technology company reported $2.44 EPS for the quarter, beating the consensus estimate of $2.40 by $0.04. The business had revenue of $595.10 million for the quarter, compared to the consensus estimate of $601.17 million. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The company’s revenue was up 15.8% on a year-over-year basis. During the same period last year, the business posted $2.13 EPS. sell-side analysts anticipate that Teleflex Incorporated will post 9.67 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Friday, March 2nd were issued a dividend of $0.34 per share. The ex-dividend date was Thursday, March 1st. This represents a $1.36 annualized dividend and a dividend yield of 0.51%. Teleflex’s payout ratio is currently 41.59%.
In related news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total transaction of $49,792.00. Following the sale, the director now directly owns 8,080 shares in the company, valued at approximately $2,011,596.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director George Babich, Jr. sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $263.38, for a total value of $658,450.00. Following the sale, the director now owns 10,583 shares in the company, valued at $2,787,350.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,259 shares of company stock worth $3,760,536. Company insiders own 2.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/17/teleflex-incorporated-tfx-shares-sold-by-goldman-sachs-group-inc.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.